argenx (ARGX) Reports ADDRESS Study of Efgartigimod SC Did Not Achieve Statistical Significance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
These 6 stocks are new Top Picks at Jefferies
December 20, 2023 3:51 PM ESTJefferies' Franchise Picks represent their analysts most confident, Buy-rated stocks within the research companys US Research portfolio. These top selections are backed by thorough analysis, distinct factors, and favorable valuations indicating potential for growth.
This month, Jefferies added 6 new ideas to the list.
argenx SE
argenx (NASDAQ: ARGX) was added to the list as Jefferies analysts consider the biotechnology companys s lead asset, Vyvgart, to be a best-in-class drug owing to its potent IgG drops, clean safety profile without dose-limiting albumin drops or effector-related adverse events, and convenient... More
Immunovant (IMVT) Trades Lower in Sympathy with argenx (ARGX)
December 20, 2023 7:40 AM ESTImmunovant (NASDAQ: IMVT) Trades Lower in Sympathy with argenx (NASDAQ: ARGX)
ARGX down 23% after ADDRESS study did not meet primary or secondary endpointsargenx SE (Euronext & Nasdaq: ARGX) announced topline results from the ADDRESS study... Moreargenx SE (ARGX) Defended at Stifel
December 20, 2023 6:17 AM ESTStifel analyst Derek Archilia reiterated a Buy rating and $560.00 price target on argenx SE (NASDAQ: ARGX)
The analyst comments "The failure of efgartigimod in Pemphigus comes as quite a surprise to us. Even on the heels of the recent failure in ITP, we... More
Deutsche Bank Issues Mea Culpa, Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
December 20, 2023 4:44 AM ESTDeutsche Bank analyst Emmanuel Papadakis downgraded argenx SE (ARGX:BB) (NASDAQ: ARGX) from Buy to Hold with a price target of EUR375.00 (from EUR500.00).
The analyst comments "ARGX today announced headline results for the next major clinical read out in the Vyvgart line-extension... More
